LT4 Stock Overview A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. More details
Rewards Risk Analysis No risks detected for LT4 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Liquidia Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Liquidia Historical stock prices Current Share Price US$13.58 52 Week High US$15.32 52 Week Low US$7.94 Beta 0.22 1 Month Change 23.57% 3 Month Change 38.01% 1 Year Change 15.48% 3 Year Change 166.27% 5 Year Change n/a Change since IPO 292.49%
Recent News & Updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 3Q 2023) Nov 15
New minor risk - Profitability Nov 13
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. See more updates
Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 3Q 2023) Nov 15
New minor risk - Profitability Nov 13
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Sep 11
Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD Aug 22
New minor risk - Profitability Aug 20
No longer forecast to breakeven Aug 20
Forecast to breakeven in 2026 Aug 19
Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Aug 19
Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.36 loss in 2Q 2023) Aug 08
New minor risk - Profitability Aug 08
No longer forecast to breakeven Aug 08
Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
Forecast to breakeven in 2026 Jul 11
No longer forecast to breakeven Jun 25
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch Jun 05
New minor risk - Share price stability Jun 03
First quarter 2024 earnings released: US$0.54 loss per share (vs US$0.18 loss in 1Q 2023) May 15
New minor risk - Profitability May 14
No longer forecast to breakeven May 14
Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024 May 09
Liquidia Corporation, Annual General Meeting, Jun 20, 2024 May 01
Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder Apr 02
CEO & Director recently sold €416k worth of stock Mar 21
Full year 2023 earnings released: US$1.21 loss per share (vs US$0.67 loss in FY 2022) Mar 14
Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024 Mar 07
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder Jan 25
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder Jan 20
Liquidia Corporation Announces Updates to Operations Leadership Jan 19 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD Jan 06 Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Jan 05
Insufficient new directors Jan 01
Forecast to breakeven in 2026 Dec 31
New minor risk - Profitability Dec 21
Independent Director recently bought €1.8m worth of stock Dec 20
New minor risk - Shareholder dilution Dec 13 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million. Dec 13
Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.14 loss in 3Q 2022) Nov 08
New major risk - Revenue and earnings growth Nov 08
Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label Sep 26
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office Sep 08
New major risk - Share price stability Aug 15
New minor risk - Profitability Aug 14
Second quarter 2023 earnings released: US$0.36 loss per share (vs US$0.15 loss in 2Q 2022) Aug 11
Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder Jul 28
Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation Jul 25
Forecast to breakeven in 2025 May 10
First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$0.67 loss per share (vs US$0.70 loss in FY 2021) Mar 18
No longer forecast to breakeven Mar 18
Forecast to breakeven in 2025 Feb 17
Forecast to breakeven in 2025 Feb 13
Forecast to breakeven in 2025 Dec 31
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 3Q 2021) Nov 09
Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
CEO & Director recently bought €246k worth of stock Sep 09 Liquidia Corporation Provides Update on Hatch-Waxman Litigation
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.13 loss in 2Q 2021) Aug 13
Liquidia Corporation to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Liquidia Corporation Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation Aug 02
Liquidia Receives Favorable Ruling in Inter Partes Review Against United Therapeutics Patent Jul 20 Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer Jun 21
Shareholder Returns LT4 DE Pharmaceuticals DE Market 7D 2.3% 4.4% 2.0% 1Y 15.5% -5.8% 15.2%
See full shareholder returns
Return vs Market: LT4 exceeded the German Market which returned 14.1% over the past year.
Price Volatility Is LT4's price volatile compared to industry and market? LT4 volatility LT4 Average Weekly Movement 6.6% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LT4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LT4's weekly volatility (7%) has been stable over the past year.
About the Company Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
Show more Liquidia Corporation Fundamentals Summary How do Liquidia's earnings and revenue compare to its market cap? LT4 fundamental statistics Market cap €1.16b Earnings (TTM ) -€114.82m Revenue (TTM ) €15.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LT4 income statement (TTM ) Revenue US$15.61m Cost of Revenue US$5.52m Gross Profit US$10.09m Other Expenses US$129.57m Earnings -US$119.47m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.41 Gross Margin 64.65% Net Profit Margin -765.37% Debt/Equity Ratio 102.4%
How did LT4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 12:52 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Liquidia Corporation is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Harrison BofA Global Research Jason Matthew Gerberry BofA Global Research Julian Harrison BTIG
Show 12 more analysts 